[vc_row][vc_column][vc_column_text css=”.vc_custom_1642518443755{margin-bottom: 0px !important;}”]Biologics have been observed to be a rapidly evolving area within biotechnology.
Cancer, autoimmune diseases, and diabetes treatments account for over 60% of the biologics market. Thus making it extremely expensive with prices increasing by the day.
According to the World Health Organization (WHO), these high prices are restricting the healthcare systems from providing affordable, population-wide access to such medicines. This creates a huge space for generic companies to manufacture biosimilars of the originator biologics whose patents have expired.
As a result, generic companies (hey there!) are continuously searching for biologics with a soon-to-be-expired label. To make it easier for them (you), we’ve collated not just the biologics names but also included other information like yearly sales, treatment, dosage, and the brand as well as company names, which could help them (you) easily choose a biologic most profitable to develop a biosimilar.
If you are interested in biologics patents, then you might also be interested in drug patents that are expiring soon. We have a list of drug patents that are expiring between 2026 to 2030. To get the list, please fill out the form below:
So, without any delay, let’s get to the list of biologics patents expiring between 2022-2027.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][mk_fancy_title color=”#2878bf” size=”32″ line_height=”80″ font_weight=”bolder” txt_transform=”uppercase” margin_bottom=”0″ font_family=”none”]Biologics Patents Expiration[/mk_fancy_title][mk_divider margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]PERJETA
Pertuzumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$4.73 Billion (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7618631B2 | April 16, 2022 |
| US8337856B2 | September 30, 2023 |
| US7862817B2 | June 1, 2025 |
| US7097840B2 | July 25, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1642580234990{margin-bottom: 0px !important;}”]Dosage: –
Company: Genentech
Treatment: HER2-positive Breast Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]VYROLOGIX
Leronlimab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$576 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7666419B2 | February 21, 2023 |
| US7851600B2 | February 21, 2023 |
| US7122185B2 | June 1, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642594678277{margin-bottom: 0px !important;}”]Dosage: –
Company: Cytodyn Inc.
Treatment: HIV Infection[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]STELARA
Ustekinumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$9.13 Billion (2021)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7279157B2 | January 13, 2022 |
| US9409984B2 | February 27, 2022 |
| US7166285B2 | May 3, 2022 |
| US8080247B2 | August 2, 2022 |
| US6902734B2 | September 25, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1642509106163{margin-bottom: 0px !important;}”]Dosage: Injection
Company: Janssen Pharmaceuticals
Treatment: Plaque Psoriasis and Psoriatic Arthritis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]BENLYSTA
Belimumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$747 Million (2019)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7605236B2 | August 5, 2022 |
| US7220840B2 | July 11, 2023 |
| US7879328B2 | July 17, 2023 |
| US7138501B2 | March 9, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1642582094229{margin-bottom: 0px !important;}”]Dosage: Injection
Company: GlaxoSmithKline
Treatment: Systemic Lupus Erythematosus[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]CYRAMZA
Ramucirumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.033 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8057791B2 | December 07, 2023 |
| US7498414B2 | January 31, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1642596991513{margin-bottom: 0px !important;}”]Dosage: –
Company: ImClone Systems Inc.
Treatment: Solid Tumors[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]ELELYSO
Taliglucerase Alfa[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8227230B2 | February 24, 2024 |
| US8741620B2 | February 24, 2024 |
| US9220737B2 | February 24, 2024 |
| US7951557B2 | July 01, 2025 |
| US8790641B2 | October 18, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1642600575208{margin-bottom: 0px !important;}”]Dosage: –
Company: Protalix and Pfizer
Treatment: Type 1 Gaucher disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]IXIARO
Japanese Encephalitis Vaccine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$106.75 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6309650 | December 30, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1642588923622{margin-bottom: 0px !important;}”]Dosage: Injection
Company: BIKEN and Sanofi Pasteur
Treatment: Japanese encephalitis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]JETREA
Ocriplasmin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$7.8 Million (2016)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7445775 | October 17, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1642602689331{margin-bottom: 0px !important;}”]Dosage: Intravitreal Injection
Company: ThromboGenics
Treatment: Symptomatic Vitreomacular Adhesion[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]KADCYLA
Trastuzumab Emtansine[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$960 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7618631B2 | April 16, 2022 |
| US8337856B2 | September 30, 2023 |
| US7862817B2 | June 1, 2025 |
| US7097840B2 | July 25, 2026 |
[/mk_table][vc_column_text css=”.vc_custom_1642580392748{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Genentech
Treatment: HER2-positive Breast Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]KALBITOR
Ecallantide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$67.3 Million (2017)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7276480 | June 6, 2023 |
[/mk_table][vc_column_text css=”.vc_custom_1642594844468{margin-bottom: 0px !important;}”]Dosage: Injection
Company: Takeda Pharmaceutical
Treatment: Hereditary Angioedema[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]MYALEPT
Metreleptin[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$71.4 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8318666B2 | October 22, 2022 |
| US7183254B2 | July 17, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1642582391831{margin-bottom: 0px !important;}”]Dosage: Injection
Company: Amryt Pharmaceutical
Treatment: Dyslipidemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]NPLATE
Romiplostim[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$227 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6835809 | January 19, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1642509298504{margin-bottom: 0px !important;}”]Dosage: Injection
Company: Amgen
Treatment: Low blood platelet counts[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]TANZEUM
Albiglutide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$160 Million (2016)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7238660B2 | December 23, 2022 |
| US7238667B2 | December 23, 2022 |
| US8071539B2 | December 23, 2022 |
| US9221896B2 | December 23, 2022 |
| US9296809B2 | December 23, 2022 |
| US7977306B2 | January 2, 2023 |
| US7799759B2 | February 11, 2023 |
| US8993517B2 | February 12, 2023 |
| US7189690B2 | October 2, 2023 |
| US7592010B2 | December 1, 2023 |
| US7521424B2 | January 20, 2024 |
| US8287859B2 | February 11, 2024 |
| US8012464B2 | May 21, 2024 |
| US8143026B2 | February 9, 2025 |
| US8211439B2 | April 11, 2025 |
| US7847079B2 | October 4, 2025 |
| US7141547B2 | April 22, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1642588112761{margin-bottom: 0px !important;}”]Dosage: Injection
Company: GlaxoSmithKline
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]VICTOZA
Liraglutide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$2.7 Billion (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6268343 | August 22, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1642582216050{margin-bottom: 0px !important;}”]Dosage: Injection
Company: Novo Nordisk
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]YERVOY
Ipilimumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.7 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US6984720 | February 8, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1642518931139{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Bristol‑Myers Squibb
Treatment: Melanoma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row]
[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]DARZALEX
Daratumumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$4.1 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7829673B2 | August 27, 2026 |
| US9187565B2 | December 5, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1642602528474{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Genmab
Treatment: Myeloma[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]BLINCYTO
Blinatumomab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$103 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7635472B2 | November 28, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1642602028625{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Micromet (acquired by Amgen)
Treatment: Acute Lymphoblastic Leukemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]CIMZIA
Certolizumab Pegol[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$2.04 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7186820B2 | February 3, 2022 |
| US7977464B2 | February 13, 2022 |
| US7012135B2 | February 13, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642579379068{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection
Company: UCB
Treatment: Crohn’s Disease, Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]ILARIS
Canakinumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$576 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7446175B2 | December 22, 2022 |
[/mk_table][vc_column_text css=”.vc_custom_1642587668959{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Novartis
Treatment: Systemic Juvenile Idiopathic Arthritis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]SIMPONI
Golimumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$576 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7521206B2 | March 20, 2022 |
| US8241899B2 | November 3, 2022 |
| US7250165B2 | February 3, 2024 |
| US7691378B2 | September 19, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642580072956{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection
Company: Janssen Biotech
Treatment: Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]TRULICITY
Dulaglutide[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$5.07 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US10369003B2 | October 15, 2024 |
| US10376376B2 | October 15, 2024 |
| US10610371B2 | October 15, 2024 |
| US11083591B2 | October 15, 2024 |
| US9056018B2 | October 15, 2024 |
| US9867712B2 | October 15, 2024 |
| US10695187B2 | June 28, 2025 |
| US8273854B2 | May 15, 2026 |
| US10130493B2 | July 17, 2026 |
| US8535379B2 | December 13, 2026 |
| US11135072B2 | April 11, 2027 |
| US7452966B2 | December 7, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1642601376296{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection
Company: Eli Lilly and Company
Treatment: Type 2 Diabetes[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]ZALTRAP
Aflibercept[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$15.88 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7399612B2 | November 6, 2023 |
| US7279159B2 | November 11, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642596733679{margin-bottom: 0px !important;}”]Dosage: Intravitreal Injection
Company: Regeneron Pharmaceuticals
Treatment: Wet Macular Degeneration and Metastatic Colorectal Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]SYLVANT
Siltuximab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7612182B2 | October 26, 2022 |
| US7955597B2 | October 26, 2022 |
| US7833786B2 | June 7, 2023 |
| US7291721B2 | September 13, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1642582534148{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Eusa Pharma
Treatment: Metastatic Renal Cell Cancer, Prostate Cancer, and Castleman’s Disease[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]LARTRUVO
Olaratumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$304.7 Million (2018)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8574578B2 | June 19, 2026 |
| US8128929B2 | December 20, 2027 |
[/mk_table][vc_column_text css=”.vc_custom_1642666838843{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Eli Lilly and Company
Treatment: Solid Tumors[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]OPDIVO
Nivolumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$7.92 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US9393301B2 | July 2, 2023 |
| US8168179B2 | July 2, 2023 |
| US9067999B1 | July 2, 2023 |
| US9073994B2 | July 2, 2023 |
| US9439962B2 | July 2, 2023 |
| US9402899B2 | February 5, 2024 |
| US7595048B2 | August 8, 2024 |
| US8728474B2 | August 8, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642595073046{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Bristol‑Myers Squibb
Treatment: Different Types of Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]PORTRAZZA
Necitumumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7598350B2 | March 21, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1642601877572{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Eli Lilly and Company
Treatment: Metastatic Squamous Non-small Cell Lung Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]PROLIA
Denosumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$4.6 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8409578B2 | June 25, 2022 |
| US8058418B2 | November 30, 2023 |
| US7364736B2 | February 19, 2025 |
[/mk_table][vc_column_text css=”.vc_custom_1642581937003{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection
Company: Amgen
Treatment: Osteoporosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]TALTZ
Ixekizumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$1.78 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8110191B2 | December 5, 2026 |
| US7838638B2 | February 4, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1642602837379{margin-bottom: 0px !important;}”]Dosage: Subcutaneous Injection
Company: Eli Lilly and Company
Treatment: Autoimmune Diseases[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]ARANESP
Darbepoetin Alfa[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$629 Million (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7217689B1 | May 15, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642601036160{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Amgen
Treatment: Anemia[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]EYLEA
Aflibercept[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
$8.36 Billion (2020)[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US7279159B2 | November 11, 2024 |
[/mk_table][vc_column_text css=”.vc_custom_1642601769098{margin-bottom: 0px !important;}”]Dosage: Intravitreal Injection
Company: Regeneron Pharmaceuticals
Treatment: Wet Macular Degeneration and Metastatic Colorectal Cancer[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]ARZERRA
Ofatumumab[/mk_fancy_title][/vc_column_inner][vc_column_inner width=”1/2″][mk_fancy_title color=”#777777″ size=”16″ font_family=”none”]Sales:
–[/mk_fancy_title][/vc_column_inner][/vc_row_inner][vc_accordions action_style=”toggle-action”][vc_accordion_tab icon=”mk-moon-inject-2″ title=”More information about this Drug”][vc_row_inner][vc_column_inner width=”1/12″][/vc_column_inner][vc_column_inner width=”10/12″][mk_table]
| Patents | Expiration Date |
|---|---|
| US8529902B2 | August 2, 2030 |
[/mk_table][vc_column_text css=”.vc_custom_1642602923884{margin-bottom: 0px !important;}”]Dosage: Intravenous Infusion
Company: Genmab
Treatment: Multiple Sclerosis[/vc_column_text][/vc_column_inner][vc_column_inner width=”1/12″][/vc_column_inner][/vc_row_inner][/vc_accordion_tab][/vc_accordions][mk_divider style=”thin_solid” margin_bottom=”40″][/vc_column][/vc_row][vc_row][vc_column][vc_column_text css=”.vc_custom_1642519179025{margin-bottom: 0px !important;}”]
Conclusion
Earlier we released a list of 91 drug patents expiring between 2020 to 2022. And while small molecule drugs still dominate the global pharmaceutical market in terms of numbers, many of the most promising new therapies for previously intractable diseases are a result of biologics. Biologics are thus becoming increasingly important to the pharmaceutical market. But having this list is one thing and using it is another.
Developing biosimilars is not going to be as smooth sailing. Generic companies will likely have to face many threats and stiff legal battles depending on the biologic they choose.
With proper threat analysis, companies can save themselves from this torment. Wanna know all about it? Just fill out the form below and we’ll get back to you in no time.
List curated by: Divya Goyal, Life Science Team Authored By: Nidhi, Marketing.
